Background: Older patients with advanced breast cancer are less likely to receive chemotherapy than younger patients. Vinorelbine is an attractive alternative in this setting because of its clinical activity and low frequency of side effects. This multicenter, phase II trial was designed to assess the safety and efficacy of intravenous vinorelbine as first-line therapy in women ^ 60 years old.
Introduction
Increasing age is a major risk factor for developing breast cancer. Approximately half of all new cases are diagnosed in women ^65 years old, at a rate nearly double that for women who are 50 to 65 years old (1400 versus 750 cases per 100,000) [1] . As the size of the older female population increases, the number of older women with breast cancer will increase. By the year 2030, the number of patients with breast cancer and survivors in the United States is expected to reach 1.4 million [2] .
Most women with advanced breast cancer ultimately receive some form of cytotoxic chemotherapy in an effort to palliate symptoms, prolong survival, or both. Unfortunately, chemotherapy frequently poses a significant challenge for older patients. Physicians are less likely to offer chemotherapy to their older breast cancer patients [3] presumably because of perceived poorer tolerance, greater risks associated with myelosuppression, and reduced efficacy compared with younger patients. When given the option, older women are less likely to accept chemotherapy [3] presumably because of concerns regarding subjective side effects such as alopecia, nausea, and vomiting. Nonetheless, older women are typically underrepresented and sometimes excluded from clinical trials, especially those involving dose intensive and dose dense strategies.
Vinorelbine tartrate (Navelbine®; Glaxo Wellcome Inc, Research Triangle Park, NC), a semisynthetic vinca alkaloid, is an attractive candidate for chemotherapy in elderly patients. In clinical trials of single agents as firstline therapy for advanced breast cancer, vinorelbine was generally well tolerated and produced objective response rates ranging from 41% to 50% [4] [5] [6] [7] [8] . Vinorelbine does not produce the subjective toxicities associated with many chemotherapeutic agents, cardiotoxicity associated with anthracyclines, nor the myalgia or neurotoxicity associated with paclitaxel. Although granulocytopenia is dose limiting, it is usually rapidly reversible and does not usually cause neutropenic fever requiring hospitalization.
Furthermore, there is evidence that vinorelbine is well tolerated by elderly patients. There were no important differences in the incidence or severity of hematologic and nonhematologic events between women who werê 65 years old (n -70) vs. younger women (n -151) in a re-analysis [9] from two multicenter trials [10, 11] . The older patients had slightly more grade 3-4 neutropenia (84% vs. 74%) but less grade 3-4 anemia (9% vs. 17%). Only 1 of the 221 patients had grade 3-4 thrombocytopenia; this patient was actually < 65 years old. The older group had more grade 3 constipation (6% vs. 3%) and grade 3 asthenia (15% vs. 8%), whereas grade 3 injection-site reaction was less common in older patients (0% vs. 2%) [9] .
We designed a prospective, phase II, multicenter study to evaluate the safety and efficacy of vinorelbine as firstline chemotherapy for advanced breast cancer in women 60 years old. The preliminary findings of this study have been presented previously [12] .
Patients and methods

Patients
Women were eligible if they had advanced breast cancer with no prior chemotherapy for metastatic disease and were ^60 years old. Breast cancer had to be microscopically confirmed and bidimensionally measurable Previous cytotoxic therapy was acceptable only as adjuvant therapy and then only if the patient had been disease free for > 12 months; radiation therapy was acceptable if it was completed > 3 weeks before study entry and did not include the only site of measurable disease; hormonal therapy had to be completed > 1 week before study entry. Patients were excluded if any of the following were present: Karnofsky performance status <70; life expectancy < 16 weeks; metastases to the central nervous system; second malignancy other than basal cell skin cancer or cervical carcinoma in situ; peripheral neuropathy except for cancer-related abnormalities; inadequate liver (> 2.0 mg total bilirubin/dl or AST more than three times upper limit of normal), kidney (>2.5 mg serum creatinine/dl), or bone marrow function (<2000 granulocytes/ul, < 100,000 platelets/ul, or <9 g hemoglobin/dl); other uncontrolled medical condition; or any condition that would prevent weekly medical follow-up and compliance with the protocol.
Each patient gave written, informed consent before registration. The protocol was reviewed and approved by the human investigations committee at each institution.
Interventions
Vinorelbine was initiated within 24 hours after study registration and administered weekly. After the first 13 weeks, vinorelbine was administered every two weeks because of patient convenience. After dilution with 0.9% sodium chloride or 5% dextrose in water, vinorelbine was administered over 6 to 10 minutes by syringe, at a concentration of 1.5-3.0 mg/ml, or from an intravenous bag, at a concentration of 0.5-2.0 mg/ml.
The initial weekly dose was 30 mg/m 2 . Modifications were based on the presence of prior infection (i.e., fever or sepsis with the previous cycle) and granulocyte count on the day of treatment. The dose was reduced to 22.5 mg/m 2 if the patient had prior infection and ^ 1500 granulocytes/ul, 15 mg/m 2 for 1000-1499 granulocytes/ul (and no prior infection), and 11.25 mg/m 2 for 1000-1499 granulocytes/ul combined with prior infection. Vinorelbine was postponed until the next scheduled treatment day for neutropenia with <1000 granulocytes/ul. Treatment was discontinued in the event of dose delay for three weeks or more, or with < 1000 granulocytes/ul for more than two weeks.
Modifications were also specified for neurologic toxicity or hepatic insufficiency, but no dose modifications were required for renal insufficiency. The dose was delayed until the next scheduled treatment day if grade ^2 neurotoxicity occurred; the patient was removed from the study if grade > 2 neurotoxicity persisted for more than two weeks. The dose was reduced to 15 mg/m 2 if total bilirubin was 2.1-3.0 mg/dl and 7.5 mg/m 2 if it was 5 3 mg/dl. A course of therapy was defined as eight weeks. Treatment was continued until there was evidence of disease progression (defined below) If, within eight weeks, there was evidence of disease progression that was not rapidly progressive or life-threatening and the patient was clinically stable, she could remain on study until her next scheduled assessment. If, at that time, her disease had stabilized and the investigator agreed, she could elect to continue. If there was further disease progression, she was removed from the study.
Palliative radiotherapy, other antineoplastic agents, and experimental drugs were not permitted. Colony-stimulating factors were used therapeutically if fever (>38°C) and granulocytopenia (< 1000 granulocytes/ul) were present. Supportive care with, for example, analgesics, antibiotics, antiemetics, antidiarrheals, and blood and blood products was permitted as needed.
Evaluation
Screening evaluation was completed within two weeks before registration and consisted of medical history, complete physical examination including neurologic evaluation, assessment of performance status, hematologic studies, serum chemistries, and tumor measurement. Adverse experiences and complete blood cell count including white blood cell count differential and platelet count were determined before each treatment. Vital signs and performance status were reevaluated every four weeks; physical examination and serum chemistries were reevaluated every eight weeks.
Tumor response was evaluated by physical examination, X-ray, or both every four weeks for the first eight weeks and then every eight weeks. When appropriate, diagnostic scans (i.e., computerized tomography, magnetic resonance imaging, or bone scans) were performed every eight weeks.
Complete response (CR) was defined as total disappearance of all cancerous lesions without the development of new malignant lesions. Partial response (PR) was defined by 50% reduction in the sum of the products of the longest perpendicular diameters of all measurable lesions without progression and without new lesions. Progressive disease (PD) was defined by 25% increase in the sum of the products of the greatest length and width of all measurable lesions over baseline, significant increase of nonmeasurable disease, or appearance of a new lesion. Stable disease (SD) was defined as failure to meet the criteria for CR, PR, and PD. CR, PR, and SD had to be documented by assessment at least four weeks later.
Duration of CR or PR was calculated from the first day of treatment to the first day of progressive disease or death. Time to PD was defined as the time from first treatment to PD, regardless of whether treatment was discontinued. If treatment was discontinued for reasons other than PD, the patient was monitored quarterly until development of PD or initiation of alternative chemotherapy.
Toxicity was graded on a modified version of the five-point scale used by the National Cancer Institute Toxicity. Intensity, severity, and attributability of adverse events were determined weekly; severity of toxicities and symptoms were recorded weekly.
Statistical considerations
Fifty patients were needed to estimate rate of tumor response with a maximum standard error of 7%. All patients who received at least one dose of vinorelbine were evaluated for toxicity and tumor response in an intent-to-treat analysis. Kaplan-Meier methods were used to estimate duration of response and time to PD.
Results
Patients
Fifty-six women (median age 72) were enrolled at six sites in the United States between 25 March 1994, and 26 October 1995. All were evaluable for efficacy and toxicity. Most were white and had cancer-related symptoms at entry (Table 1) . Slightly more than half had estrogenreceptor positive disease; most had received prior treatment, usually hormonal therapy. Slightly more than half had predominantly visceral disease; three-fourths had at least two metastatic sites. A single eligibility restriction was waived for five patients who were judged otherwise to be good candidates for the study: two with a previous history of uterine cancer and one each for elevated AST, inadequate hemoglobin level, and radiotherapy within three weeks.
The median time on study was 25.5 weeks (range 1-121 weeks); the median number of doses received was 15.5 (range 1-56 doses). The median dose intensity of vinorelbine, defined as the dose received in the first eight-week course divided by the number of scheduled doses (i.e., eight), was 20.6 mg/m 2 /week. Doses were delayed during the first course in 71% of patients; a median of two doses per patient were delayed.
Response to vinorelbine
The objective response rate was 38% (95% CI: 24%-51%; Table 2 ), which consisted of two CRs (4%) and 19 PRs (34%). Twenty-one patients (38%) had SD, which lasted ^6 months in nine patients (16%). The overall success rate (CR + PR + SD ^6 months) was 54%. Of seven patients who had received anthracycline-based adjuvant therapy, one had a CR and three had PRs.
The median time to disease progression was nine months for patients with objective responses (i.e., duration of response), 6.5 months for patients with SD, and six months for all patients (Figure 1) . Twenty percent of patients were censored because they had progressed at the time of analysis or when they went off study.
Safety
The major dose-limiting toxicity was hematologic, which was primarily manifested as granulocytopenia without neutropenic fever (Table 3) . Eighty percent of patients had at least one episode of grade 3 or 4 granulocytopenia. Grade 3-4 nadirs lasted a mean of nine days (range 2-21), and 49% of first episodes occurred at week 3 of the first course. Nine patients received granulocytecolony stimulating factors once (n -8) or daily for four days (n = 1). Thirteen patients (23%) had fever attributable to vinorelbine, but only six (11%) had febrile neutropenia. Four patients were hospitalized because of granulocytopenia and associated fever. One patient developed sepsis related to vinorelbine (see below). Four (20) 3 (5) 56 (100) 12 (21) 32 (57) 12 (21) 32 (57) 19 (34) 13 (23) 10 (18) 14 (25) 14 (25) 28 ( patients (7%) had grade 3 anemia; one received erythropoietin. Eight patients (14%) received a blood transfusion. One patient had grade 3 thrombocytopenia.
Three patients (5%) died within 30 days of treatment. One died from progression of breast cancer; another, from pneumonia and chronic obstructive pulmonary disease. The third was the only death considered to be A« (n = 56) CR/PR (n = 21) Table 4 . Nonhematologic toxicities occurring in 2= 5% of patients and reasonably or possibly attributable to study drug. (54) 4(7) 53 (95) 18 (32) 27 (48) 52 (93) 2 (4) 4(7) 6 (11) 4 ( drug related; the patient was hospitalized for febrile neutropenia, developed sepsis, and succumbed to respiratory failure.
Grade 3-4 nonhematologic toxicity was uncommon and consisted of asthenia (7%); nausea and generalized pain (5%); vomiting, chest pain, abdominal pain, and elevated AST (4%); fever, diarrhea, constipation, and injection-site reaction (2%) ( Table 4 ). Grade 1-2 alopecia was reported in 23% of patients. Neurotoxicity was mild (grade 1-2); relatively infrequent; and consisted of decreased reflexes (14%), hypesthesia (11%), and paresthesia (9%). Seven patients (13%) experienced grade 1-2 pain at the injection site. There were no cases of ileus. Two patients were taken off study due to adverse experiences attributed to vinorelbine: one experienced severe nausea and moderate vomiting after a single dose; the other was withdrawn due to moderate fatigue after being on study for 13 weeks. (23) 10 (18) 9 (16) 7 (13) 5 (9) 5 (9) 24 (43) 19 (34) 11 (20) 9 (16) 6 (11) 8 (14) 6 (11) 5 (9) 3 (5) 3 (5) 26 (51) 13 (23) 5 (9) 3 (5) 3 (5) Grade 3
This is the first trial of intravenous vinorelbine specifically designed for older women with advanced breast cancer and one of the few trials to evaluate efficacy and tolerability of any drug in older women. Vinorelbine appears to have meaningful clinical activity in elderly patients; it produced objective responses in 38% of patients. When patients with stable disease for more than six months were considered, the overall success rate was 54%. Furthermore, the median time to disease progression was nine months in the subset of patients with stable disease for more than six months as well as in patients with objective responses. Survival data were not collected because vinorelbine was used as first-line therapy in this phase II study, and survival would have been influenced by subsequent treatment. The results of three smaller trials involving vinorelbine and elderly women have been published since the current trial was initiated. Sorio et al. [13] administered vinorelbine 30 mg/m 2 as first-, second-, or third-line therapy on days 1 and 8 every three weeks; the objective response rate was 30% in 20 evaluable women who were > 65 years old. In a retrospective analysis from the same institution, vinorelbine 25 mg/m 2 on days 1 and 8 every three weeks produced objective response rates of 42% in all 31 women who were > 65 years old, 66% in 12 women who received vinorelbine as first-line therapy, and 26% in 19 women who had previously received chemotherapy for metastatic disease [14] . Gladieff et al. [15] administered mitoxantrone 10 mg/m 2 on day 1 followed by vinorelbine 20 mg/m 2 on days 1 and 8 every three weeks as first-line therapy to 25 women who were > 70 years old; the objective response rate was only 22%, but the median duration of response was 13 months.
The current results compare favorably with those of other single-agent regimens used as first-line therapy in elderly women with advanced breast cancer. Repetto et al. [17] reported that mitoxantrone produced partial responses in 26% of 27 women who were ^ 68 years old; the median durations of response and overall survival were six and eight months, respectively. Chevallier et al. [16] reported that pirarubicin produced an overall response rate of 25% in 30 women who were > 70 years old; the median time to progression in all patients was three months.
Response rates from this trial also compare favorably with those of cyclophosphamide, methotrexate, and 5-fluorouracil (5-FU; CMF) and other combinations used as first-line therapy in elderly women with advanced breast cancer. Taylor et al. [18] reported that the classical CMF schedule produced a 38% overall response rate in patients who were > 65 years old; whereas Engelsman et al. [19] reported that classical CMF produced a 48% response rate in postmenopausal women, but only 14% were > 65 years old. Gelman and Taylor [20] reported that a modified CMF regimen produced overall response rates of 36% to 53% and median durations of response of 5.0 to 10.7 months in patients who were > 65 years old. Hainsworth et al. [21] reported that mitoxantrone, 5-FU, and leucovorin produced a 45% response rate in postmenopausal women, but only 42% of women were ^ 50 years old. Mammoliti et al. [22] reported that mitoxantrone, fluorouracil, and levo-leucovorin produced partial responses in 50% of 24 women who were > 65 years old; the median durations of progression-free and overall survival were nine and 14 months, respectively. Unlike the patients enrolled in the other studies, half of these patients had been previously treated for metastatic disease [22] .
In a major review of women with metastatic breast cancer, Ibrahim et al. [23] retrospectively analyzed 1011 women who were > 65 years old (24%) or 50 to 64 years old (76%) and were treated with doxorubicin-based chemotherapy at M.D. Anderson Cancer Center from 1973 to 1984. Although the objective response rate was higher for younger patients (67% vs. 51%, P = 0.001), no significant differences were seen in dose intensity; overall survival; time to disease progression; median platelet and WBC nadirs; or the incidences of fever, neutropenic fever, and death from infection.
Few other publications specifically address the relative activity and safety of chemotherapy in older women with metastatic breast cancer. Christman et al. [24] concluded that older women had similar response rates, time to disease progression, survival, and toxic effects compared with younger women in an age-based analysis of the Piedmont Oncology Association's experience with combination regimens for metastatic breast cancer such as cyclophosphamide, doxorubicin, and fluorouracil; CMF; and other variants of the Cooper regimen. Mammoliti et al. [22] and Repetto et al. [17] concluded that chemotherapy produced similar outcomes in older and younger women based on observations from phase II trials of elderly women.
Vinorelbine was reasonably well tolerated by elderly women in the current trial. As expected, granulocytopenia was dose limiting, resulting in a median dose intensity of 21 mg/m /week. Two of the smaller trials involving vinorelbine and elderly patients yielded similar dose intensities because of granulocytopenia. Sorio et al. [13] reported that the mean dose intensity of singleagent vinorelbine was 67%. Gladieff et al. [15] reported that only 57% of patients received > 75% of the planned dose when vinorelbine was administered after mitoxantrone. Bruno et al. [4] reported a mean dose intensity of 76% with first-line vinorelbine for metastatic breast cancer in patients who were not age restricted, which suggests that the need for reduced dosing is not unique to elderly patients. Furthermore, Sorio et al. [13] concluded that the pharmacokinetic profile of vinorelbine does not provide a rationale for reducing the dosage in the elderly based on the disposition observed in 10 elderly patients.
Importantly, vinorelbine did not cause the subjective side effects associated with other cytotoxic agents. There were no episodes of grade 3 or 4 alopecia. Grade 3 or 4 nausea and vomiting occurred in only 6% and 4% of patients, respectively. Injection site reactions occurred in only 2% of patients, which is consistent with a previous report showing that rapid infusion over 6 to 10 minutes minimizes the venous irritation sometimes associated with peripheral administration [25] .
Vinorelbine appears to offer a promising alternative for the management of advanced breast cancer for elderly patients who are concerned by the subjective side effects of cytotoxic chemotherapy. In fact, response rates, tolerability, and dose intensity in our patients approximated that reported for women who were not age restricted [4] [5] [6] [7] [8] . Randomized studies are warranted to compare the activity of vinorelbine with that of other regimens, such as other well-tolerated single agents and combination regimens, in elderly patients.
